Value Microcaps Zip Code Changers

[Rawnoc]

Quarter was disappointing vs. what I expected but was still profitable with solid sales and near term future still looks very bright. SG&A up as you pointed out, but I guess we should have expected that as they make a bigger effort to launch the new needles especially since they had some expenses related to getting the FDA safety designation -- expenses that shouldn't be repeated going forward.

So I expect higher sales coupled with lower expenses going forward. Next Q report could and should be a record one across the board. The safety designation from the FDA came in at the very beginning of the quarter.

How about you. Thoughts?